Helsinki-based glucose tracking for non-diabetics wearable technology startup Veri has raised $4 million in a combined pre-seed and seed round that was led by PROFounders. The round(s) also saw participation from Lifeline Ventures, Accel, and several angel investors, including Johannes Schildt, CEO and co-founder of Kry/Livi, Kristian Ranta, CEO and co-founder of Meru Health, and other undisclosed individuals. The funding is slated to begin shipments of the device to US-based customers, as well as further fuel growth in Europe.
Founded in early 2020 by Anttoni Aniebonam, Verneri Jäämuru, and Frans Lehmusvaara, the Veri (literally translated as blood in Finnish) wearable device provides users with a simple and effective way of tracking their blood sugar levels. The ultimate goal here is achieving optimal metabolic health, i.e. preventative medicine.
With only 12% of American adults metabolically healthy, Veri’s delivery is timely. Adding to this striking statistic, the pandemic highlighted another frightening statistic: 78% of individuals who were hospitalised for COVID were overweight or obese. In other words, there’s a silent crisis happening in the United States right now, one that Veri is seeking to address.
“Veri is one of the most impactful biowearable platforms that we have ever seen. It is like having the best nutritionist in the world standing by your side 24-7, helping you understand how your food and lifestyle choices are affecting your personal metabolism in real-time,” says Dr. Vimal Ramjee, a cardiologist, culinary medicine specialist, and the Director of Health at Veri.
Veri is currently available in Europe, and as of yesterday, in the US as well. But if you’ve got your hopes set on one delivered by tomorrow, stand in line, as the company reports some 50,000 individuals already on a waitlist.
“Metabolic health is one of the strongest predictors of lifespan. We are on a mission to provide people with an effortless and deeply personalized way of eating, helping everyone reach their health goals and prevent the more distressing diseases,” concludes CEO Aniebonam.